Drug Profile
Research programme: Alzheimer's disease therapeutics - Neurim Pharmaceuticals
Alternative Names: Neu-AZ1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Neurim Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Israel
- 13 Dec 2012 Preclinical trials in Alzheimer's disease in Israel (unspecified route)